(MedPage Today) — SAN ANTONIO — More than 70% of patients with advanced triple-negative breast cancer (TNBC) responded to an investigational bispecific antibody targeting PD-L1 and VEGF-A plus chemotherapy, a preliminary study showed.
Overall…
Source link : https://www.medpagetoday.com/meetingcoverage/sabcs/119040
Author :
Publish date : 2025-12-16 16:30:00
Copyright for syndicated content belongs to the linked Source.
